Allogeneic Hematopoietic Progenitor Cell Therapy
Customize your policy alerts
Sign up for tdsfidelis Policy MC.CP.MP.249 alerts
Get alerted when Policy MC.CP.MP.249 changes without checking for updates manually.
Monitor payer policy activity
Establishes medical-necessity criteria for Omisirge (omidubicel) and RegeneCyte (HPC Cord Blood) for Medicare Advantage members when applicable Medicare coverage criteria are unavailable.
RegeneCyte was added as a covered medically necessary allogeneic hematopoietic progenitor cell therapy with criteria for unrelated-donor transplantation.
Omisirge coverage was expanded to include members six years of age and older with severe aplastic anemia following reduced-intensity conditioning.
The policy description and background were updated to incorporate evidence and criteria for severe aplastic anemia treated with Omisirge.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.